Beta
ManageSearchChatDiscover
351824

Pristimerin Protects Against Doxorubicin-Induced Cardiomyopathy and Fibrosis

Article

Last updated: 29 Dec 2024

OverviewSimilar Items

Subjects

-

Tags

-

Abstract

Pristimerin (Pris) is triterpenoid compound with many 
biological effects. Until now, nothing is known about 
its effect on doxorubicin (DOX)-induced 
cardiotoxicity. Hence, this study investigated the 
impact of Pris on DOX-induced cardiotoxic effects. 

DOI

10.21608/cvrepj.2019.351824

Volume

3

Article Issue

1

Related Issue

47325

Issue Date

2019-06-01

Receive Date

2024-04-25

Publish Date

2019-06-01

Print ISSN

2636-4204

Online ISSN

2636-4212

Article File

CVREPJ3518241559340000.pdf

PDF . 35.6kB

Link

https://cvrepj.journals.ekb.eg/article_351824.html

Detail API

https://cvrepj.journals.ekb.eg/service?article_code=351824

Order

351,824

Type

Abstracts

Type Code

3,139

Publication Type

Journal

Publication Title

Cardiovascular Research Prove Journal

Publication Link

https://cvrepj.journals.ekb.eg/

MainTitle

Pristimerin Protects Against Doxorubicin-Induced Cardiomyopathy and Fibrosis

Details

Type

Article

Created At

20 Dec 2024